Literature DB >> 10408419

Long-term nature of depression.

M E Thase1.   

Abstract

Many, if not most, people with depression are at high risk to develop a recurrent and potentially chronic disorder, characterized by deleterious effects on vocational, social, and family functioning. Recent evidence also suggests that recurrent episodes of severe depression are associated with changes in brain function that further heighten vulnerability and functional impairment. The best way to deal with these sobering problems is prevention via vigorous treatment of the index episode (to produce complete remission) and more routine use of longer term models of prophylactic therapy. After briefly reviewing the relevant data on epidemiology and natural history, this article focuses on the 4 "arms" of preventative treatment: psychoeducation, pharmacotherapy, adherence, and psychotherapy. Like the modern approach to treatment of hypertension, a conscientious and integrated approach to preventative therapy saves lives and has profoundly beneficial effects for our patients, their loved ones, and society.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10408419

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  7 in total

1.  Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study.

Authors:  Jay D Amsterdam; Justine Shults
Journal:  Am J Psychiatry       Date:  2010-04-01       Impact factor: 18.112

Review 2.  Venlafaxine extended-release: a review of its use in the management of major depression.

Authors:  K Wellington; C M Perry
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 3.  Escitalopram : a review of its use in the management of major depressive and anxiety disorders.

Authors:  John Waugh; Karen L Goa
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 4.  Once-weekly fluoxetine.

Authors:  A J Wagstaff; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 5.  Escitalopram: a pharmacoeconomic review of its use in depression.

Authors:  Katherine F Croom; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 6.  Spotlight on the pharmacoeconomics of escitalopram in depression.

Authors:  Katherine F Croom; Greg L Plosker
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 7.  Migraine and psychiatric disorders: comorbidities, mechanisms, and clinical applications.

Authors:  S M Baskin; Todd A Smitherman
Journal:  Neurol Sci       Date:  2009-05       Impact factor: 3.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.